Premium
Compliance in European pharmacovigilance: how compliant is compliant?
Author(s) -
Koster PhD Maria C,
Teeuw PhD Bart,
Cockburn MB ChB MRCGP FFPM Iain
Publication year - 2000
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/1099-1557(200011)9:6<473::aid-pds530>3.0.co;2-q
Subject(s) - pharmacovigilance , audit , medicine , receipt , workflow , patient safety , risk analysis (engineering) , warrant , quality (philosophy) , identification (biology) , process management , adverse effect , pharmacology , computer science , business , database , accounting , health care , philosophy , finance , epistemology , economics , economic growth , botany , biology
The emergence of European requirements for safety reporting has resulted in systems geared towards the timely collection and submission of reports at the cost of the quality of the reports or their evaluation. This change in focus has been engendered by system audits concentrating on ‘easy to measure targets’ such as time frames. The real purpose of pharmacovigilance, the identification and communication of potential safety concerns, may be lost in the effort to expedite. By common consensus there are certain safety issues that warrant special attention including serious unexpected events, changes in frequency of known adverse events, those involving special populations, overdosage, or potential drug – drug interactions. Rationalizing and prioritizing workflow management during safety processing is required to optimize the utilization of available resources. This paper provides a basis for discussion on suitable standards for the receipt, processing and distribution of safety reports and proposes possible benchmarks as a measurement of competent pharmacovigilance practice. Copyright © 2000 John Wiley & Sons, Ltd.